Literature DB >> 183556

Persistence of virus-specific IgM and clinical recovery after Japanese encephalitis.

R Edelman, R J Schneider, A Vejjajiva, R Pornpibul, P Voodhikul.   

Abstract

We have searched for evidence of a chronic Japanese encephalitis virus (JEV) infection in six Thai patients convalescing from acute Japanese encephalitis (JE) in whom JEV-specific IgM antibody was last detected 116 to 350 days after their acute illness. These six patients were compared with 94 other JE patients matched for age, sex and serological response and in whom JEV-specific IgM was either short-lived (less than 90 days) or not tested. All patients were evaluated for the presence or absence of seven abnormal neurological signs over a 1- to 2-year period. During the first 30 days of illness the mean numbers (+/- S.E.M.) of abnormal signs per patients for the IgM and control groups were 3.8 +/- 0.3 and 2.3 +/- 0.1, respectively (P less than 0.01). After 1 year the six IgM patients still had significantly more abnormal neurological signs than controls (1.3 +/- 0.3 and 0.6 +/- 0.1, respectively [P less than 0.01]). By 2 years, the IgM group showed no neurological impairment; examination of cerebrospinal fluids revealed no evidence of subclinical viral infections. The recovery of the six IgM patients between 1 and 2 years after their relatively severe acute illness suggests that IgM antibody persistence was related to acute virulence rather than chronicity of the JEV infection.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 183556     DOI: 10.4269/ajtmh.1976.25.733

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  17 in total

1.  Japanese encephalitis virus latency in peripheral blood lymphocytes and recurrence of infection in children.

Authors:  S Sharma; A Mathur; V Prakash; R Kulshreshtha; R Kumar; U C Chaturvedi
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

Review 2.  Arboviruses and the central nervous system.

Authors:  D E Griffin
Journal:  Springer Semin Immunopathol       Date:  1995

3.  Humoral immunity against Francisella tularensis after natural infection.

Authors:  P Koskela; A Salminen
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

4.  Enzyme-linked immunosorbent assay (ELISA) for detection of specific IgA antibodies to mumps virus.

Authors:  B Halevy; I Sarov
Journal:  J Clin Pathol       Date:  1982-10       Impact factor: 3.411

5.  Persistence of immunoglobulin G and immunoglobulin M antibodies after postnatal rubella infection determined by solid-phase radioimmunoassay.

Authors:  O H Meurman
Journal:  J Clin Microbiol       Date:  1978-01       Impact factor: 5.948

6.  BK antibody and virus-specific IgM responses in renal transplant recipients, patients with malignant disease, and healthy people.

Authors:  A J Flower; J E Banatvala; I L Chrystie
Journal:  Br Med J       Date:  1977-07-23

7.  Cell-mediated and humoral immunity induced by a live Francisella tularensis vaccine.

Authors:  P Koskela; E Herva
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

8.  Detection of Japanese encephalitis virus immunoglobulin M antibodies in serum by antibody capture radioimmunoassay.

Authors:  D S Burke; A Nisalak
Journal:  J Clin Microbiol       Date:  1982-03       Impact factor: 5.948

9.  Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination.

Authors:  Katherine B Gibney; Srilatha Edupuganti; Amanda J Panella; Olga I Kosoy; Mark J Delorey; Robert S Lanciotti; Mark J Mulligan; Marc Fischer; J Erin Staples
Journal:  Am J Trop Med Hyg       Date:  2012-10-29       Impact factor: 2.345

10.  Persistence of virus-reactive serum immunoglobulin m antibody in confirmed west nile virus encephalitis cases.

Authors:  John T Roehrig; Denis Nash; Beth Maldin; Anne Labowitz; Denise A Martin; Robert S Lanciotti; Grant L Campbell
Journal:  Emerg Infect Dis       Date:  2003-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.